Piper Jaffray analyst Edward Tenthoff lowered his price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $20.50 (from $23.00) after its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE